Oligonucleotides and methods for detecting hepatitis C viral nucleic acids

• US 6,946,245 B2
• Filed: 12/04/2001
• Issued: 09/20/2005
• Est. Priority Date: 12/04/2001
• Status: Expired due to Fees

• Current Assignee: Quest Diagnostics Investment Incorporated
• Original Assignee: Quest Diagnostics Investments Incorporated (Quest Diagnostics Incorporated)
• Inventors: Baumann, Russell, Hamdan, Hasnah, Lewinski, Michael
• Primary Examiner(s): Parkin, Jeffrey S.
• Assistant Examiner(s): LI, BAO Q
• Application Number:
  US10/011,855
• Publication Number:
  US 20030104582A1
• Time in Patent Office: 1,386 Days
• Field of Search: 435/5, 435/6, 435/8, 435/91.1, 536/24.3, 536/24.32, 536/23.7, 536/23.72
• US Class Current: 435/5
• CPC Class Codes: C12Q 1/707 non-A, non-B Hepatitis, excluding hepatitis D

Abstract

The present invention provides methods and compositions for determining the presence and/or amount of HCV nucleic acids in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting HCV nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the HCV assay.

Claims

1. A method for detecting the presence or amount of HCV nucleic acid in a test sample, comprising:

(a) introducing a phage-HCV nucleic acid hybrid into said sample, wherein said hybrid comprises a phage sequence and a HCV sequence;

(b) reverse transcribing and amplifying HCV nucleic acid if presence in said sample and generating a phage-HCV amplicon using a pair of oligonucleotide primers having the sequences set forth in SEQ ID NO;

1 and SEQ ID NO;

2;

(c) hybridizing said amplified HCV nucleic acid with an HCV oligonucleotide probe complementary to HCV sequence in the presence of an enzyme that cleaves said probe when said probe hybridizes to said HCV nucleic acid, wherein said HCV probe is conjugated to a detectable label that generates a detectable signal upon said cleavage;

(d) hybridizing said phage-HCV nucleic acid amplicon to a control oligonucleotide probe complementary to the phage sequence wherein said probe is conjugated to a detectable label that generates a detectable signal upon said cleavage; and

(e) detecting a signal from said detectable label, wherein said signal indicates the presence or amount of HCV nucleic acid in said test sample.

2. A method according to claim 1, wherein said probe is conjugated to 2′

-chloro-7′

-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC) and 6 -carboxytetramethylrhodamine (TAMRA).

3. The method of claim 1, wherein said test sample is selected from the group consisting of serum, blood, plasma, cerebral spinal fluid, synovial fluid, and urine.

4. The method of claim 1, wherein nucleic acids are purified from said sample prior to said reverse transcription and amplification step (a).

5. The method of claim 2, wherein said phage-HCV ribonucleic acid hybrid are introduced into said test sample prior to isolating nucleic acid from said sample.

6. The method of claim 1, wherein said HCV probe comprises a sequence set forth in SEQ ID NO:

3.

7. The method of claim 1, wherein said phage sequence is from lambda phage.

8. The method of claim 7, wherein said control probe comprises the sequence set forth in SEQ ID NO:

6.

9. The method of claim 1, wherein said control probe is conjugated to 6-carboxyfluorescein (FAM) and 6-carboxytertramethylrhodomaine (TAMRA).

10. The method of claim 1, wherein said phage-HCV nucleic acid hybrid comprises an RNP polymerase.